• Publications
  • Influence
Effect of Food on Pharmacokinetics of an Inhaled Drug: A Case Study with a VLA‐4 Antagonist, HMR1031
HMR1031 is a potent and specific antagonist of the integrin VLA‐4 (α4β1) binding to vascular cell adhesion molecule‐1 (VCAM‐1) and fibronectin. HMR1031 is an inhaled drug being developed for theExpand
In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver
Abstract 1. A novel oral chymase inhibitor, SUN13834, is under clinical development for the treatment of atopic dermatitis (AD). In this study, in vitro and in vivo metabolic profiles of SUN13834Expand
Mass Balance Study of [14C]M100240, a Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, in Healthy Male Subjects
[4S-[4&agr;,7&agr;(R*),12b&bgr;]]-7[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1-a][2]benzazepine-4-carboxylic acid (M100240) is an acetate thioester ofExpand
Development of a Dry Powder Inhaler, the Ultrahaler®, Containing Triamcinolone Acetonide Using In Vitro-In Vivo Relationships
Triamcinolone acetonide (TAA) is safe and effective corticosteroid that is marketed as an MDI (metered dose inhaler) (Azmacort) for the treatment of asthma. A novel dry powder inhaler (DPI), theExpand
Imaging orthopedic hardware with an emphasis on hip prostheses.
This article reviews contemporary evaluation of hip prostheses, emphasizing both the accepted use of conventional radiographs, arthrograms, and scintigraphy, as well as the evolving use of CT and MRExpand
Pharmacokinetics, Pharmacodynamics, and Safety of a Lipid-Lowering Adenosine A1 Agonist, RPR749, in Healthy Subjects
RPR749 and its methylated metabolite are orally active and selective adenosine A1 agonists that can inhibit lipolysis and lower plasma triglyceride levels in a variety of animal models. RPR749 alsoExpand
Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler
A pharmacoscintigraphic study was conducted to compare the dose deposition of HMR 1031 from the existing nebulizer formulation and the new Ultrahaler device to help determine the doses for futureExpand
Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteers
The pharmacokinetics of an adenosine agonist, AMP 579, following intravenous administration were evaluated. Single AMP 579 doses of 20 to 150 μg/kg were infused intravenously over 6 hours using aExpand
Estimating Mass Balance for Inhaled Drugs in Humans: An Example with a VLA‐4 Antagonist, IVL745
IVL745 is an inhaled VLA‐4 antagonist developed for the treatment of asthma. Following inhalation (Inh), a fraction of the drug is deposited in the oropharynx, and the rest is deposited in the lungs.Expand
Does Erythromycin Have Anti‐Inflammatory Effects Independent of Its Antimicrobial Action?
  • C. Oo, B. Shah
  • Medicine
  • Journal of clinical pharmacology
  • 1 April 2012